Z-VAD-FMK C22H30FN307
To Order Contact us: stephen@expresspharmapulse.com
Z-VAD-FMK |
A1902-25 |
ApexBio |
25 mg |
EUR 514 |
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
Z-VAD-FMK |
A1902-5 |
ApexBio |
5 mg |
EUR 224 |
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
Z-VAD-FMK |
A1902-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 224 |
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2. |
Caspase-Family Inhibitor Z-VAD-FMK |
1010-100 |
Biovision |
|
EUR 196 |
Caspase-Family Inhibitor Z-VAD-FMK |
1010-20C |
Biovision |
|
EUR 196 |
SRB-VAD-FMK [Sulforhodamine B-VAD-FMK] |
13472 |
AAT Bioquest |
25 Tests |
EUR 132 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12352200
|
Z-VAD-FMK (Pan-specific caspase inhibitor) |
SIH-557-1MG |
Stressmarq |
1 mg |
EUR 193 |
Description: The substance Z-VAD-FMK is a pan-specific caspase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is lyophilized solid or wax which is May be dissolved in DMSO (10 mg/ml). |
TF4-VAD-FMK |
13471 |
AAT Bioquest |
25 Tests |
EUR 132 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12352200
|
mFluor™ 450-VAD-FMK |
13475 |
AAT Bioquest |
25 Tests |
EUR 132 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12352200
|
mFluor™ 510-VAD-FMK |
13476 |
AAT Bioquest |
25 Tests |
EUR 132 |
- R-phrase: R20, R21, R22
- H-Phrase: H303, H313, H333
- Symbol for dangerous compounds: Xn
- UNSPEC Code: 12352200
|
Z-IETD-FMK |
B3232-1 |
ApexBio |
1 mg |
EUR 328 |
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells. |
Z-IETD-FMK |
B3232-5 |
ApexBio |
5 mg |
EUR 456 |
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells. |
Z-IETD-FMK |
B3232-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 1001 |
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells. |
Z-LEHD-FMK |
B3233-1 |
ApexBio |
1 mg |
EUR 350 |
Description: Z-LEHD-FMK is a specific and irreversible inhibitor of caspase-9 [1].Caspase-9 is an initiator caspase and plays an important role in the mitochondrial death pathway. |
Z-LEHD-FMK |
B3233-5 |
ApexBio |
5 mg |
EUR 879 |
Description: Z-LEHD-FMK is a specific and irreversible inhibitor of caspase-9 [1].Caspase-9 is an initiator caspase and plays an important role in the mitochondrial death pathway. |
Z-DEVD-FMK |
A1920-1 |
ApexBio |
1 mg |
EUR 113 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
Z-DEVD-FMK |
A1920-10 |
ApexBio |
10 mg |
EUR 340 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
Z-DEVD-FMK |
A1920-25 |
ApexBio |
25 mg |
EUR 514 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
Z-DEVD-FMK |
A1920-5 |
ApexBio |
5 mg |
EUR 224 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
Z-DEVD-FMK |
A1920-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 293 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
Z-DEVD-FMK |
A1920-S |
ApexBio |
Evaluation Sample |
EUR 81 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
Z-DQMD-FMK |
A1921-1 |
ApexBio |
1 mg |
EUR 113 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
Z-DQMD-FMK |
A1921-10 |
ApexBio |
10 mg |
EUR 340 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
Z-DQMD-FMK |
A1921-25 |
ApexBio |
25 mg |
EUR 514 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
Z-DQMD-FMK |
A1921-5 |
ApexBio |
5 mg |
EUR 224 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
Z-DQMD-FMK |
A1921-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 432 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
Z-DQMD-FMK |
A1921-S |
ApexBio |
Evaluation Sample |
EUR 81 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
Z-VDVAD-FMK |
A1922-1 |
ApexBio |
1 mg |
EUR 177 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
Z-VDVAD-FMK |
A1922-10 |
ApexBio |
10 mg |
EUR 630 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
Z-VDVAD-FMK |
A1922-25 |
ApexBio |
25 mg |
EUR 978 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
Z-VDVAD-FMK |
A1922-5 |
ApexBio |
5 mg |
EUR 398 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
Z-VDVAD-FMK |
A1922-S |
ApexBio |
Evaluation Sample |
EUR 81 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
Z-VEID-FMK |
A1923-1 |
ApexBio |
1 mg |
EUR 177 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
Z-VEID-FMK |
A1923-10 |
ApexBio |
10 mg |
EUR 630 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
Z-VEID-FMK |
A1923-25 |
ApexBio |
25 mg |
EUR 978 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
Z-VEID-FMK |
A1923-5 |
ApexBio |
5 mg |
EUR 398 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
Z-VEID-FMK |
A1923-S |
ApexBio |
Evaluation Sample |
EUR 81 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
Z-WEHD-FMK |
A1924-1 |
ApexBio |
1 mg |
EUR 113 |
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
Z-WEHD-FMK |
A1924-10 |
ApexBio |
10 mg |
EUR 340 |
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
Z-WEHD-FMK |
A1924-25 |
ApexBio |
25 mg |
EUR 514 |
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
Z-WEHD-FMK |
A1924-5 |
ApexBio |
5 mg |
EUR 224 |
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
Z-VAD-FMK C22H30FN307